Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:
NCT01086605
First received: March 12, 2010
Last updated: July 13, 2015
Last verified: July 2015
  Purpose

RATIONALE: Drugs used in chemotherapy, such as pixantrone dimaleate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pixantrone dimaleate in different ways may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying how well pixantrone dimaleate works in treating patients with HER2-negative metastatic breast cancer.


Condition Intervention Phase
Breast Cancer
Drug: pixantrone dimaleate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Alliance for Clinical Trials in Oncology:

Primary Outcome Measures:
  • Proportion of confirmed tumor responses (complete or partial response) [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to disease progression [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • 6-month progression-free survival rate [ Time Frame: At 6 months ] [ Designated as safety issue: No ]
  • Overall survival time [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Change in quality of life [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
  • Incidence of adverse events as assessed by NCI CTCAE version 4.0 [ Time Frame: Up to 1 year after treatment ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 56
Study Start Date: May 2010
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I
Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Drug: pixantrone dimaleate
Given IV
Experimental: Arm II
Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Drug: pixantrone dimaleate
Given IV

Detailed Description:

OBJECTIVES:

Primary

  • To assess the proportion of confirmed tumor responses in patients with HER2-negative metastatic breast cancer treated with pixantrone dimaleate.

Secondary

  • To describe the distribution of progression-free survival (PFS) times of patients treated with this drug.
  • To assess the 6-month PFS rate in patients treated with this drug.
  • To describe the overall survival of patients treated with this drug.
  • To assess the adverse event profile of this drug in these patients.
  • To evaluate the quality of life and patient-reported symptoms of patients treated with this drug.
  • To evaluate quantitative and qualitative changes of circulating tumor cells after pixantrone dimaleate therapy. (Correlative study)
  • To bank blood and tissue samples for future evaluation of pharmacogenetic and/or proteomic markers. (Correlative study)

OUTLINE: This is a multicenter study. Patients are randomized according to prior doxorubicin treatment ( yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Some patients undergo blood sample collection at baseline and periodically during study for circulating tumor cells analysis by CellSearch System and mRNA isolation assays.

Patients complete quality-of-life questionnaires using the Linear Analogue Self Assessment (LASA6) and the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at baseline and periodically during study.

After completion of study therapy, patients are followed up every 3-6 months for up to 5 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Histologically or cytologically confirmed adenocarcinoma of the breast and clinical evidence of metastatic breast cancer
  • Pre-treatment requirements:

    • Must have been previously treated in neoadjuvant, adjuvant or metastatic setting with anthracycline and/or taxane
    • Must have received 2-3 prior chemotherapy treatment regimens; NOTE: If NO prior (neo)adjuvant chemotherapy, patient must have received a minimum of 2 prior chemotherapy regimens in the metastatic setting; NOTE: If prior (neo)adjuvant chemotherapy HAS been given, patient must have received at least 1 prior chemotherapy regimen in the metastatic setting
    • Prior hormonal therapy allowed in the neo-adjuvant, adjuvant, or metastatic setting; unlimited prior hormonal therapy is allowed
  • Patients must have measurable disease
  • Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
  • Hemoglobin >= 10.0 g/dL
  • Absolute neutrophil count (ANC) >= 1,500/mm^3
  • Platelet count >= 100,000/mm^3
  • Total bilirubin =< 1.5 times upper limit of normal (ULN)
  • Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) serum glutamate pyruvate transaminase (SGPT)(alanine aminotransferase [ALT]) =< 5 times ULN
  • Serum creatinine =< 1.5 times ULN
  • Left ventricular ejection fraction (LVEF) >= 50% and electrocardiogram (EKG) normal within institutional normal limits completed =< 22 days prior to registration
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Life expectancy > 3 months
  • Ability to complete questionnaire(s) by themselves or with assistance
  • Patient has provided written informed consent
  • Willingness to return to North Central Cancer Treatment Group (NCCTG) enrolling institution for follow-up

Exclusion criteria:

  • Any of the following:

    • Pregnant women
    • Nursing women
    • Men or women of childbearing potential who are unwilling to employ adequate contraception (as determined by the treating physician)
  • Stage III or IV invasive cancer (other than breast cancer) in =< 3 years prior to registration (with the exception of non-melanoma skin cancer)
  • HER2 positive breast cancer (3+ by immunohistochemistry [IHC] or fluorescent in situ hybridization [FISH] amplified) breast cancer by American Society for Clinical Oncology [ASCO]/College of American Pathologists [CAP] guidelines
  • Has already received lifetime cumulative treatment with doxorubicin equivalent to > 400 mg/m^2
  • > 3 prior chemotherapy regimens for breast cancer; NOTE: This number includes (neo)adjuvant chemotherapy, if given; if (neo)adjuvant chemotherapy HAS been given it counts as one (1) regimen
  • Major surgery, chemotherapy, or immunologic therapy =< 3 weeks prior to registration

    • NOTE: If patient has received prior treatment with bevacizumab, treatment on this trial should not begin until >= 4 weeks after the last dose of bevacizumab
  • Radiotherapy =< 4 weeks prior to registration, except if to a non-target lesion only

    • NOTES:

      • Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed
      • If patient receives single dose radiation for palliation or radiation to non-target lesion, they may immediately proceed to registration without waiting
      • Acute adverse events from radiation must have resolved to =< grade 1 (according to current version of National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE])
  • Evidence of active brain metastasis including leptomeningeal involvement

    • NOTE: central nervous system (CNS) metastasis controlled by prior surgery and/or radiotherapy is allowed; to be considered controlled, there must be at least 2 months of no symptoms or evidence of progression prior to study entry and corticosteroid therapy given to control brain edema must have been discontinued
  • Uncontrolled hypertension (blood pressure [BP] > 160/90 mmHg on >= 2 occasions at least 5 minutes apart); (patients who have recently started or adjusted antihypertensive medications are eligible providing that BP is < 140/90 mmHg on any new regimen for >= 3 different observations in >= 14 days)
  • Clinically significant cardiovascular or cerebrovascular disease, including any history of the following at any time prior to registration:

    • Myocardial infarction
    • Unstable angina pectoris
    • New York Heart Association (NYHA) class II or greater congestive heart failure
    • Uncontrolled or clinically significant cardiac arrhythmia (patients with controlled atrial fibrillation are eligible)
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • History of allergy or hypersensitivity to drug product excipients or agents chemically similar to pixantrone
  • Currently receiving treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered

    • NOTE: Patient may not enroll in such clinical trials while participating in this study; exception may be granted for trials related to symptom management (cancer control) which do not employ hormonal treatments or treatments that may block the path of the targeted agents used in this trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01086605

  Show 230 Study Locations
Sponsors and Collaborators
Alliance for Clinical Trials in Oncology
Investigators
Study Chair: Kostandinos Sideras, MD Mayo Clinic
  More Information

Additional Information:
No publications provided

Responsible Party: Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier: NCT01086605     History of Changes
Other Study ID Numbers: N1031, NCCTG-N1031, CDR0000667253, NCI-2011-02021, U10CA180821, U10CA025224
Study First Received: March 12, 2010
Last Updated: July 13, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Alliance for Clinical Trials in Oncology:
HER2-negative breast cancer
male breast cancer
recurrent breast cancer
stage IV breast cancer
stage IIIC breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Pixantrone
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on August 02, 2015